Brief: Cantex Receives FDA "Study May Proceed" Letter For Phase 2 Clinical Trial Of Unmethylated Glioblastoma Deug Azeliragon
27/02/2023 13:13
Feb 27 (Reuters) - vTv Therapeutics Inc VTVT.O :
* CANTEX RECEIVES FDA "STUDY MAY PROCEED" LETTER FOR PHASE 2
CLINICAL TRIAL OF AZELIRAGON FOR THE TREATMENT OF UNMETHYLATED
GLIOBLASTOMA
Source text for Eikon: ID:nPnbGTBZqa
Further company coverage: VTVT.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on vTv Therapeutics
See all newsBrief: Vtv Therapeutics Announces FDA Orphan Drug Designation For Hppd In Sickle Cell Disease
vTv Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
vTv Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
vTv Therapeutics Q2 net loss widens on higher trial costs
Brief: VTv Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)